Skip to main content
. 2015 May 5;6(16):14399–14412. doi: 10.18632/oncotarget.3882

Figure 4. BMP-inhibitors are targets of the miR-200 family.

Figure 4

A. qRT-PCR and western blot analysis show targeting of ZEB1, NOG, FST and CHRDL1 by miR-200c or miR-141 (pre-miR or miRVana from life technologies) in MDA-BoM-1833. qRT-PCR data are represented as mean +SD. B. Inhibition of the miR-200 family with antagomiRs in MDA-MB-231 results in increased mRNA and protein expression of NOG, and slightly increased mRNA expression of ZEB1, analyzed by qRT-PCR and western blot. qRT-PCR data are represented as mean +SD. C. NOG 3′UTR-luciferase reporter activity is reduced after miR-200c overexpression (pre-miR) in MDA-MB-231. Sequential mutation of the miR-200c binding sites in the NOG 3′UTR prevents downregulation. Luciferase activity relative to control is represented as mean +SD.